Organon Pharma Indonesia Tbk. vs Semen Indonesia (Persero) Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Semen Indonesia (Persero) Tbk. trades at Rp1,695 (market cap 11.68T, 20.89M 24h volume). The key difference: Semen Indonesia (Persero) Tbk. is far larger — about 111.9× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMGR | |
|---|---|---|
Market Cap | 104.4B | 11.68T |
Volume | — | 20.89M |
Lot | — | 208.88K |
Turnover | — | 35.38B |
Average Price | — | 1,693.71 |
Value | — | 35.38B |
Indicative Equilibrium Price | — | 1,695 |
Indicative Equilibrium Volume | — | 10.02K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Semen Indonesia (Persero) Tbk was established on March 25,1953 as NV Pabrik Semen Gresik. On April 17, 1961,NV Pabrik Semen Gresik was transformed into a state enterprise (Persero) by Government Regulation No. 132 year 1961, and subsequently became PT Semen Gresik (Persero). Semen Gresik is a cement producer which was formerly fully owned by the government. On July 1995 the company shareholders meeting agreed to acquired 100% share of two state owned cement producer companies, namely PT. Semen Tonasa and PT. Semen Padang.
Read more on SMGR →